Enfuvirtide
Also referenced as: Fuzeon
An HIV fusion-inhibitor peptide used with other antiretroviral medicines.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Fuzeon is FDA-approved with other antiretrovirals for treatment-experienced patients with ongoing HIV-1 replication despite therapy.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An HIV fusion-inhibitor peptide used with other antiretroviral medicines.
Fuzeon is FDA-approved with other antiretrovirals for treatment-experienced patients with ongoing HIV-1 replication despite therapy.
It is not effective as an appropriate standalone HIV regimen and does not broadly boost immunity.
Why It's Being Studied
- HIV-1 therapy
- Viral membrane fusion
Mechanism of Action
Binding HIV gp41 prevents viral fusion with the target-cell membrane.
Binding HIV gp41 prevents viral fusion with the target-cell membrane. It is not effective as an appropriate standalone HIV regimen and does not broadly boost immunity.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- HIV-1 therapy
- Viral membrane fusion
- Subcutaneous approved medicine
Evidence Summary
TORO studies support virologic benefit when added to optimized background therapy in treatment-experienced HIV-1 infection.
Higher tiers carry more weight. Filled tiers have evidence for Enfuvirtide; tap to read it.
- TORO studies support virologic benefit when added to optimized background therapy in treatment-experienced HIV-1 infection.
1 cited sources.
- Prescribing label1
Human clinical evidence
- TORO studies support virologic benefit when added to optimized background therapy in treatment-experienced HIV-1 infection.
Reported Adverse Events in Research
- Injection-site reactions are very common; hypersensitivity, pneumonia concerns and resistance are relevant.
Limitations of Current Evidence
- It is not effective as an appropriate standalone HIV regimen and does not broadly boost immunity.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Enfuvirtide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Enfuvirtide — prescribing label